Index	Inst	Title	PI	Local PI	MemberID	Phase	Sponsor	Sponsor Type	Type	Age	Trial IDs	Tumor Type(s)
1	Fred Hutch	MRI and Gene Expression in Diagnosing Patients with Ductal Breast Cancer In Situ	Constance D. Lehman	Habib Rahbar		No phase specified	ECOG-ACRIN Cancer Research Group; NCI	Coop Group; NCI	 Diagnostic, Natural history/Epidemiology	 18 and over	 E4112, NCI-2014-01261, ECOG-E4112, NCT02352883	Breast
2	Fred Hutch	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Stage II-IV HIV-Associated Hodgkin Lymphoma	Paul G. Rubinstein	Manoj Menon		Phase I/II	National Cancer Institute	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 AMC-085, NCI-2013-00046, 085, 2014-003678-18, PAMC-085_A05PAMDREVW01, NCT01771107	Lymphoma
3	Fred Hutch	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Ann Elizabeth Woolfrey	Ann Elizabeth Woolfrey		No phase specified	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 Under 65	 1410.00, NCI-2010-00802, FHCRC-1410.00, NCT00112593	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
4	Fred Hutch	Collecting and Studying Blood and Tissue Samples from Patients with Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer	Robert Bruce Montgomery	Robert Bruce Montgomery		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Biomarker/Laboratory analysis	 18 and over	 6932, NCI-2014-01087, 6932p, NCT01050504	Bladder; Prostate; Urinary Tract; Mets
5	Fred Hutch	A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)	Ann Elizabeth Woolfrey	Ann Elizabeth Woolfrey		No phase specified	Center for International Blood and Marrow Transplant Research; National Marrow Donor Program	Other; NCI	 Health services research, Supportive care	 Any age	 10-CBA, NCI-2014-02344, NCI-2013-01898, NCI-2014-01018, NCT01351545	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
6	Fred Hutch	Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients with Soft Tissue Sarcoma	Darin Davidson	Darin Davidson		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 7487, NCI-2011-02488, NCT01446809	Sarcoma
7	Fred Hutch	Collecting and Storing Residual Tissue, Blood, and Body Fluids in Patients with Cancer	James H. Doroshow	Stephen Schmechel		No phase specified	National Cancer Institute	NCI	 Tissue collection/Repository	 18 and over	 06-C-0213, NCI-2013-02055, 060213, 06C0213-H, 334184, P7002, NCT00900198	Any
8	Fred Hutch	Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening	Nancy Kiviat	Nancy Kiviat		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Diagnostic, Health services research, Screening	 21 and over	 7489, NCI-2013-00745, NCT01550783	Cervix
9	Fred Hutch	Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients with Relapsed or Refractory Acute Myeloid Leukemia	Ann E Dahlberg	Ann E Dahlberg		No phase specified	Fred Hutchinson Cancer Research Center; NCI; Seattle Children’s Research Institute Center for Clinical and Translational Research	IIT; NCI; Other	 Treatment	 2 to 30	 2584.00, NCI-2012-01724, 2378, 2584, NCT01701323	Leukemia
10	Fred Hutch	Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer	Celestia Savoye Higano	Celestia Savoye Higano		No phase specified	Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; Prostate Cancer Foundation; NCI	IIT; NCI; Other	 Biomarker/Laboratory analysis, Treatment	 18 and over	 7819, NCI-2012-01898, NCT01703065	Prostate
11	Fred Hutch	Brentuximab Vedotin in Treating Patients With Relapsed or Refractory CD30+ Lymphoma	Ajay Kumar Gopal	Ajay Kumar Gopal		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 7808, NCI-2012-01696, NCT01703949	Lymphoma
12	Fred Hutch	Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T	Celestia Savoye Higano	Celestia Savoye Higano		No phase specified	Dendreon Corporation	Pharma	 Biomarker/Laboratory analysis	 18 and over	 P11-4, NCI-2015-00139, NCT01727154	Prostate
13	Fred Hutch	Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer	Robert Bruce Montgomery	Robert Bruce Montgomery		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 7846, NCI-2012-02136, NCT01731912	Prostate
14	Fred Hutch	Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients with Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia	Roland Bruno Walter	Roland Bruno Walter		No phase specified	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 18 and over	 2642.00, NCI-2013-00481, 2642, NCT01804101	Leukemia; Myelodysplastic Syndrome
15	Fred Hutch	Outpatient Induction Chemotherapy in Treating Patients with Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	Pamela Sue Becker	Pamela Sue Becker		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Natural history/Epidemiology	 18 to 59	 7910, NCI-2013-00483, NCT01807091	Leukemia; Myelodysplastic Syndrome
16	Fred Hutch	Prospective Cohort for the Evaluation of Biomarkers Following HCT (BMT CTN 1202)	John Andrew Hansen	John Andrew Hansen		No phase specified	Medical College of Wisconsin; Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute; National Heart Lung and Blood Institute	Other; NCI; NHLBI	 Biomarker/Laboratory analysis, Natural history/Epidemiology	 Not specified	 BMTCTN1202, NCI-2014-01454, U10HL069294-11, NCT01879072	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
17	Fred Hutch	FLT PET in Measuring Treatment Response in Patients with Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer	Hannah Margaret Linden	Hannah Margaret Linden		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Biomarker/Laboratory analysis, Diagnostic	 18 and over	 7536, NCI-2013-01380, NCT01928186	Breast
18	Fred Hutch	Collecting, Analyzing, and Storing Samples From Patients with Metastatic, Triple Negative Breast Cancer Receiving Cisplatin	Anthony Blau	Anthony Blau		No phase specified	University of Washington Medical Center; Nci	IIT; NCI	 Biomarker/Laboratory analysis, Tissue collection/Repository	 18 and over	 8132, NCI-2013-01654, ITOMIC-001, UW13022, NCT01957514	Breast; Mets
19	Fred Hutch	Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma	Seth Pollack	Seth Pollack		No phase specified	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 2705.00, NCI-2013-01779, NCT01957709	Sarcoma
20	Fred Hutch	SPECT/CT in Measuring Lung Function in Patients with Lung Cancer Undergoing Radiation Therapy	Jing Zeng	Jing Zeng		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Diagnostic	 19 and over	 8180, NCI-2013-01774, NCT01982123	Lung
21	Fred Hutch	MRI and PET Imaging in Predicting Treatment Response in Patients with Stage IB-IVA Cervical Cancer	Nina Andrea Mayr	Nina Andrea Mayr		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Diagnostic	 18 and over	 8118, NCI-2013-01935, NCT01992861	Cervix Cancer
22	Fred Hutch	Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts	Constance D. Lehman	Constance D. Lehman		No phase specified	GE Healthcare	Pharma	 Screening	 18 and over	 124.03-2013-GES-0003, NCI-2014-01332, NCT02042456	Breast
23	Fred Hutch	Decitabine and Cytarabine in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm	Pamela Sue Becker	Pamela Sue Becker		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Treatment	 60 and over	 9019, NCI-2014-00769, NCT02121418	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
24	Fred Hutch	F-18 FES PET in Measuring Hormone Expression in Patients with Primary, Recurrent or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy	Hannah Margaret Linden	Hannah Margaret Linden		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Biomarker/Laboratory analysis, Diagnostic	 18 and over	 7184, NCI-2013-02342, NCT02149173	Breast; Mets
25	Fred Hutch	18F-FLT PET/CT in Measuring Cell Proliferation in Patients with Brain Tumors	Jason Rockhill	Jason Rockhill		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Diagnostic	 18 and over	 7754, NCI-2013-02162, NCT02167204	Brain; Mets
26	Fred Hutch	Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)	Geoffrey Raymond Oxnard	Rafael Santana-Davila		No phase specified	National Cancer Institute	NCI	 Biomarker/Laboratory analysis, Natural history/Epidemiology	 18 and over	 A151216, NCI-2014-01509, NCT02200497, NCT02194738	Lung
27	Fred Hutch	Proton Beam Radiation Therapy in Treating Patients with Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy	Jing Zeng	Jing Zeng		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Treatment	 19 and older	 9148, NCI-2014-01468, NCT02204761	Lung
28	Fred Hutch	Ibrutinib in Treating Patients with Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphoma	Ajay Kumar Gopal	Ajay Kumar Gopal		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 9107, NCI-2014-01573, NCT02207062	Lymphoma
29	Fred Hutch	Telemonitoring Device in Managing Outpatient Care of Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia after Intensive Chemotherapy	Roland Bruno Walter	Roland Bruno Walter		No phase specified	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Supportive care	 18 to 75	 9105, NCI-2014-01680, NCT02226497	Leukemia; Myelodysplastic Syndrome
30	Fred Hutch	Expressive Writing in Improving the Wellbeing or Comforting Capacity of Caregivers of Patients with Cancer	Linda Ko	Linda Ko		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Supportive care	 18 and over	 9216, NCI-2014-02511, NCT02339870	Any
31	Fred Hutch	Taking Care of Her Program in Patients with Stage III or IV Ovarian Cancer and Spouse Caregivers	Frances Lewis	Frances Lewis		No phase specified	University of Washington Medical Center; NCi	IIT; NCI	 Supportive care	 Not specified	 9306, NCI-2015-00325, NCT02401321	Ovary
32	Fred Hutch	Iodine I 131 Monoclonal Antibody BC8 before Autologous Stem Cell Transplant in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	Ajay Kumar Gopal	Ajay Kumar Gopal		Phase I	Fred Hutchinson Cancer Research Center; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 2238.00, NCI-2010-00128, FHCRC-2238.00, IR-6844, MCLI-07-002, NCT00860171	Lymphoma
33	Fred Hutch	A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer	Celestia Savoye Higano	Celestia Savoye Higano		Phase I	Genentech Inc.	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 DST4964g, NCI-2011-03433, GO00768, NCT01283373	Prostate; Mets
34	Fred Hutch	Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome	Brenda M. Sandmaier	Brenda M. Sandmaier		Phase I	Fred Hutchinson Cancer Research Center; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 50 and over	 2468.00, NCI-2011-00150, 2468, 2468.00A, NCT01300572	Leukemia; Lymphoma; Myelodysplastic Syndrome
35	Fred Hutch	A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab	Ajay Kumar Gopal	Ajay Kumar Gopal		Phase I	Pfizer Inc	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 B1641001, NCI-2012-00880, 2011-002799-17, NCT01307267	Lymphoma; Solid Tumors
36	Fred Hutch	Gene Therapy for Fanconi Anemia	Pamela Sue Becker	Pamela Sue Becker		Phase I	Fred Hutchinson Cancer Research Center; National Heart Lung and Blood Institute; NCI	IIT; NCI; NHLBI	 Biomarker/Laboratory analysis, Treatment	 Not specified	 2097.00, NCI-2011-00202, NCT01331018	N/A
37	Fred Hutch	Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients	John Michael Pagel	John Michael Pagel		Phase I	JW Pharmaceutical Corporation	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 JW-231A-101, NCI-2011-03495, NCT01398462	Leukemia
38	Fred Hutch	Radiation Therapy, Cisplatin, and Etoposide in Treating Patients with Non-small Cell Lung Cancer That Cannot Be Removed by Surgery	Shilpen Patel	Shilpen Patel		Phase I	University of Washington Medical Center; NCI	NCI	 Treatment	 not specified	 7506, NCI-2011-01752, NCT01411098	Lung
39	Fred Hutch	Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)	Laura Q.M. Chow	Laura Q.M. Chow		Phase I	Bristol-Myers Squibb	Pharma	 Treatment	 18 and over	 CA209-012, NCI-2012-00350, NCT01454102	Lung; Mets
40	Fred Hutch	90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma	William I. Bensinger	William I. Bensinger		Phase I	Fred Hutchinson Cancer Research Center; NCI	NCI	 Treatment	 18 to 65	 2450.00, NCI-2010-02041, NCT01503242	Myeloma
41	Fred Hutch	Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma	William I. Bensinger	William I. Bensinger		Phase I	Acetylon Pharmaceuticals	Pharma	 Treatment	 18 and over	 ACE-MM-101, NCI-2012-01280, NCT01583283	Myeloma
42	Fred Hutch	A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects	Sarah E. Sherr Leary	Sarah E. Sherr Leary		Phase I	GlaxoSmithKline	Pharma	 Biomarker/Laboratory analysis, Treatment	 1 month to 17 years	 116013, NCI-2013-00631, NCT01677741	Peds; Solid Tumors
43	Fred Hutch	Monoclonal Antibody Therapy before Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoid Malignancies	Ajay Kumar Gopal	Ajay Kumar Gopal		Phase I	Fred Hutchinson Cancer Research Center; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 2361.00, NCI-2012-01505, NCT01678443	Lymphoma
44	Fred Hutch	Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma	Han Win Tun	Marc Charles Chamberlain		Phase I	Mayo Clinic in Florida; NCI		 Biomarker/Laboratory analysis, Treatment	 18 and over	 MC1281, NCI-2012-01948, Mod12-003419-17, NCT01722305	Lymphoma
45	Fred Hutch	Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma	Elena Gabriela Chiorean	Elena Gabriela Chiorean		Phase I	PRISM BioLab Co., Ltd.; inVentiv Health	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 PRI-724-102, NCI-2013-00907, NCT01764477	Pancreas; Mets
46	Fred Hutch	Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)	Mary Lenora (Nora) Disis	Mary Lenora (Nora) Disis		Phase I	EMD Serono	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 EMR 100070-001, NCI-2013-02214, 2013-002834-19, NCT01772004	Esophageal; Melanoma; Prostate; Lung; Bladder; Stomach; Ovary; Kidney; Head & Neck; Mets
47	Fred Hutch	Ado-Trastuzumab Emtansine in Treating Patients with HER2-Positive Metastatic or Locally Advanced Breast Cancer that Cannot Be Removed by Surgery	Vijayakrishna K. Gadi	Vijayakrishna K. Gadi		Phase I	University of Washington Medical Center; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 7900, NCI-2013-00552, CC-7900, NCT01816035	Breast; Mets
48	Fred Hutch	Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus	Missak Haigentz	Corey Casper		Phase I	National Cancer Institute	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 AMC-087, NCI-2013-00740, NCT01822522	Solid Tumors; Mets
49	Fred Hutch	AZD8186 First Time In Patient Ascending Dose Study	Celestia Savoye Higano	Celestia Savoye Higano		Phase I	AstraZeneca Pharmaceuticals LP	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 D4620C00001, NCI-2013-02191, NCT01884285	Prostate; Lung; Breast; Mets
50	Fred Hutch	A Safety Study of SGN-CD33A in AML Patients	Roland Bruno Walter	Roland Bruno Walter		Phase I	Seattle Genetics	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 SGN33A-001, NCI-2013-01719, NCT01902329	Leukemia
51	Fred Hutch	ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer	Evan Ya-Wen Yu	Evan Ya-Wen Yu		Phase I	Agensys; Seattle Genetics	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 AGS15E-13-1, NCI-2013-02093, NCT01963052	Urinary Tract; Mets
52	Fred Hutch	A Safety Study of SGN-LIV1A in Breast Cancer Patients	Jennifer Marie Specht	Jennifer Marie Specht		Phase I	Seattle Genetics	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 SGNLVA-001, NCI-2013-02245, NCT01969643	Breast; Mets
53	Fred Hutch	A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia	Pamela Sue Becker	Pamela Sue Becker		Phase I	Amgen, Inc.	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 20120234, NCI-2014-00603, NCT02016729	Leukemia
54	Fred Hutch	A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma	Shailender Bhatia	Shailender Bhatia		Phase I	Immune Design	Pharma	 Treatment	 18 and over	 IDC-G100-2013-001, NCI-2014-01333, NCT02035657	Skin; Mets
55	Fred Hutch	NY-ESO-1 Specific T Cells after Cyclophosphamide in Treating Patients with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma	Seth Pollack	Seth Pollack		Phase I	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 to 85	 2720.00, NCI-2013-02464, NCT02059850	Sarcoma; Mets
56	Fred Hutch	Safety Study of Anti-LAG-3 in CLL, HL, NHL and MM	Ajay Kumar Gopal	Ajay Kumar Gopal		Phase I	Bristol-Myers Squibb	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 CA224-022, NCI-2014-01120, NCT02061761	Leukemia; Lymphoma; Myeloma
57	Fred Hutch	Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916	Edward Norton Libby	Edward Norton Libby		Phase I	GlaxoSmithKline	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 117159, NCI-2014-00817, NCT02064387	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
58	Fred Hutch	MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)	Laura Q.M. Chow	Laura Q.M. Chow		Phase I	AstraZeneca Pharmaceuticals LP	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 D791PC00001, NCI-2014-00735, NCT02088112	Lung; Mets
59	Fred Hutch	Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer	William Proctor Harris	William Proctor Harris		Phase I	Polaris Group	Pharma	 Treatment	 18 and over	 POLARIS2013-005, NCI-2014-02490, NCT02101593	Liver
60	Fred Hutch	A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1	Seth Pollack	Seth Pollack		Phase I	Immune Design	Pharma	 Treatment	 18 and over	 ID-LV305-2013-001, NCI-2014-01153, NCT02122861	Melanoma; Sarcoma; Ovary; Breast; Lung
61	Fred Hutch	Vaccine Therapy in Treating Patients with HER2-Negative Stage III-IV Breast Cancer	Mary Lenora (Nora) Disis	Mary Lenora (Nora) Disis		Phase I	University of Washington Medical Center; NCi	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 9140, NCI-2014-01070, 137, NCT02157051	Breast
62	Fred Hutch	TLR4 agonist GLA-SE and Radiation Therapy in Treating Patients with Metastatic Sarcoma	Seth Pollack	Seth Pollack		Phase I	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 B1641003, NCI-2014-01800, KEYNOTE-0036, NCT02179918	Sarcoma; Mets
63	Fred Hutch	Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)	Pamela Sue Becker	Pamela Sue Becker		Phase I	Abbvie; Genentech Inc.	Pharma	 Biomarker/Laboratory analysis, Treatment	 65 and over	 M14-358, NCI-2014-01763, 2014-000687-18, NCT02203773	Leukemia
64	Fred Hutch	Safety Study of SGN-CD70A in Cancer Patients	John A. Thompson	John A. Thompson		Phase I	Seattle Genetics	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 SGN70A-001, NCI-2014-01875, NCT02216890	Kidney; Lymphoma
65	Fred Hutch	A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma	Brian Gerald Till	Brian Gerald Till		Phase I	Hoffmann-La Roche	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 GO29383, NCI-2014-02375, 2014-001812-21, NCT02220842	Lymphoma
66	Fred Hutch	Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer	Celestia Savoye Higano	Celestia Savoye Higano		Phase I	Emergent Product Development Seattle, LLC; MorphoSys AG	Pharma	 Biomarker/Laboratory analysis, Treatment	 Not specified	 401, NCI-2015-00276, NCT02262910	Prostate; Mets
67	Fred Hutch	Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors	Elena Gabriela Chiorean	Elena Gabriela Chiorean		Phase I	Bristol-Myers Squibb	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 CA014-001, NCI-2015-00318, FS10214100, NCT02286219	Mets; Breast; Stomach; Esophageal
68	Fred Hutch	A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML)	Roland Bruno Walter	Roland Bruno Walter		Phase I	Genentech Inc.	Pharma	 Biomarker/Laboratory analysis, Treatment	 65 and over	 M14-387, NCI-2015-00216, 2014-002610-23, NCT02287233	Leukemia
69	Fred Hutch	A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer	Laura Q.M. Chow	Laura Q.M. Chow		Phase I	Incyte Corporation; Genentech Inc.; F Hoffmann-La Roche Limited	Pharma	 Treatment	 18 and over	 INCB 24360-110, NCI-2015-00841, NCT02298153	Lung; Mets
70	Fred Hutch	NY-ESO-1-Specific T Cells in Treating Patients with Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy	Seth Pollack	Seth Pollack		Phase I	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 2721.00, NCI-2014-02154, 2721, 2721.00A, NCT02319824	Sarcoma; Mets
71	Fred Hutch	A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML	Roland Bruno Walter	Roland Bruno Walter		Phase I	Seattle Genetics	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 SGN33A-002, NCI-2014-02680, NCT02326584	Leukemia
72	Fred Hutch	Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)	Renato Goncalves Martins	Renato Goncalves Martins		Phase I	Pfizer Inc	Pharma	 Treatment	 18 and over	 INCB 24360-110, NCI-2015-00841, NCT02298153	Lung; Mets
73	Fred Hutch	Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant	Brenda M. Sandmaier	Brenda M. Sandmaier		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 Under 75	 1825.00, NCI-2010-00230, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
74	Fred Hutch	Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Mohamed L. Sorror	Mohamed L. Sorror		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 Any age	 1840.00, NCI-2009-01594, FHCRC-1840.00, 5910, NCT00104858	Leukemia; Lymphoma
75	Fred Hutch	Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders	Brenda M. Sandmaier	Brenda M. Sandmaier		Phase II	Fred Hutchinson Cancer Research Center; NCI; NHLBI	NCI; NHLBI	 Treatment	 Any age	 2056.00, NCI-2010-00237, FHCRC-2056.00, 6171, NCT00397813	Myelodysplastic Syndromes 
76	Fred Hutch	Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients with Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders	Lauri M Burroughs	Lauri M Burroughs		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 Under 55	 2032.00, NCI-2010-00192, 2032, FHCRC-2032.00, 6297, NCT00358657	N/A
77	Fred Hutch	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients with Immunodeficiency or Other Nonmalignant Inherited Disorders	Lauri M Burroughs	Lauri M Burroughs		Phase II	Fred Hutchinson Cancer Research Center; NCI; NHLBI	IIT; NCI; NHLBI	 Treatment	 55 and under	 2007.00, NCI-2009-01550, FHCRC-2007.00, 6301, NCT00553098	N/A
78	Fred Hutch	Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients with Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome	Johnnie Jose Orozco	Johnnie Jose Orozco		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 18 and over	 2186.00, NCI-2010-00404, FHCRC-2186.00, NCT00589316	Leukemia; Myelodysplastic Syndrome
79	Fred Hutch	Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematologic Disease	Colleen Delaney	Colleen Delaney		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 6 months to 45 years	 2010.00, NCI-2010-00190, FHCRC 2010.00, Protocol 2010, 6095, NCT00719888	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
80	Fred Hutch	Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer	Rachel B. Salit	Rachel B. Salit		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 Any age	 2239.00, NCI-2009-01551, 2239, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
81	Fred Hutch	Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer	Jennifer Marie Specht	Jennifer Marie Specht		Phase II	University of Washginton Medical Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 Not specified	 6628, NCI-2010-00041, FHCRC-6628, UWCC-6628, UWHSD# 33866, GENENTECH-FHCRC-6628, NCT00733408	Breast; Mets
82	Fred Hutch	Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who are Undergoing Umbilical Cord Blood Transplant	Colleen Delaney	Colleen Delaney		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 Under 65	 2275.00, NCI-2010-00299, FHCRC-2275.00, IR-6800, NCT00796068	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
83	Fred Hutch	Bendamustine Hydrochloride in Treating Patients with Recurrent or Progressive Anaplastic Glioma	Marc Charles Chamberlain	Marc Charles Chamberlain		Phase II	University of Washginton Medical Center; NCI; National Comprehensive Cancer Network	IIT; NCI; NCCN	 Treatment	 18 and over	 6803, NCI-2010-00714, UWCC-6803, FHCRC-6803, IR-6803, NCCN-C01, NCT00823797	Brain
84	Fred Hutch	Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer	Ann Elizabeth Woolfrey	Ann Elizabeth Woolfrey		Phase II	Fred Hutchinson Cancer Research Center; NCI; National Institute of Allergy and Infectious Disease	IIT; NCI; NIAID	 Biomarker/Laboratory analysis, Treatment	 75 and under	 2212.00, NCI-2009-01244, NCT00968630	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
85	Fred Hutch	Bortezomib and Vorinostat as Maintenance Therapy after Autologous Stem Cell Transplant in Treating Patients with Non-Hodgkin Lymphoma	Leona A. Holmberg	Leona A. Holmberg		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 18 and over	 2292.00, NCI-2009-01302, X05287, NCT00992446	Lymphoma
86	Fred Hutch	Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients with High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	Mohamed L. Sorror	Mohamed L. Sorror		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 0 to 75	 2241.00, NCI-2009-01334, NCT01008462	Leukemia; Lymphoma; Myeloma
87	Fred Hutch	Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Hematologic Malignancies	Rachel B. Salit	Rachel B. Salit		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 Not specified	 2372.00, NCI-2009-01433, 2372, NCT01028716	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
88	Fred Hutch	Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy	George Earl Georges	George Earl Georges		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 70 and under	 2260.00, NCI-2010-00403, FHCRC-2260.00, 6733, FHCRC-IR-6733, NCT00716066	N/A
89	Fred Hutch	Treosulfan and Fludarabine Phosphate before Donor Stem Cell Transplant in Treating Patients with Nonmalignant Inherited Disorders	Lauri M Burroughs	Lauri M Burroughs		Phase II	Fred Hutchinson Cancer Research Center; NCI; NHLBI; medac GmbH	IIT; NCI; NHLBI; Pharma	 Treatment	 Under 55	 2256.00, NCI-2010-01277, FHCRC-2256.00, IR-6935, NCT00919503	N/A
90	Fred Hutch	Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors	Saro H. Armenian	Larissa A. Korde		Phase II	City of Hope Comprehensive Cancer Research Center; NCI	NCI	 Biomarker/Laboratory analysis, Prevention	 25 and over	 08218, NCI-2010-01976, 115422, NCT01196936	Any
91	Fred Hutch	Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant	Brenda M. Sandmaier	Brenda M. Sandmaier		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Supportive care, Treatment	 Not specified	 2206.00, NCI-2010-02222, NCT01251575	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
92	Fred Hutch	Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients with Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant	Brenda M. Sandmaier	Brenda M. Sandmaier		Phase II	Brenda M. Sandmaier	Brenda M. Sandmaier	 Biomarker/Laboratory analysis, Treatment	 not specified	 2430.00, NCI-2010-02247, 2430.00A, NCT01252667	Leukemia
93	Fred Hutch	Phenelzine Sulfate and Docetaxel in Treating Patients with Prostate Cancer with Progressive Disease after First-Line Therapy with Docetaxel	Tomasz M. Beer	Peter S. Nelson		Phase II	OHSU Knight Cancer Institute; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 IRB00005688, NCI-2010-02037, 5688, MR00045508, OHSU-5688, SOL-09105-LM, NCT01253642	Prostate
94	Fred Hutch	Bortezomib and Rituximab in Treating Patients with Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation	Robert W. Chen	Leona A. Holmberg		Phase II	City of Hope Comprehensive Cancer Research Center; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 19 and over	 10137, NCI-2010-02343, 109117, 118601, X05337, NCT01267812	Lymphoma
95	Fred Hutch	Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.	Christina S Baik	Christina S Baik		Phase II	GlaxoSmithKline	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 113928, NCI-2011-03522, BRF113928, NCT01336634	Lung; Mets
96	Fred Hutch	PET-Directed Therapy in Treating Patients with Limited-Stage Diffuse Large B-Cell Lymphoma	Daniel O. Persky	Oliver W. Press		Phase II	SWOG; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 S1001, NCI-2011-02673, CDR0000700624, SWOG-S1001, NCT01359592	Lymphoma
97	Fred Hutch	PI3K Inhibitor BKM120 in Treating Patients With Metastatic Castration-Resistant Prostate Cancer	Andrew J. Armstrong	Evan Ya-Wen Yu		Phase II	Duke University Medical Center; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 Pro00027410, NCI-2013-02200, NCT01385293	Prostate; Mets
98	Fred Hutch	Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Patients with Previously Untreated Mantle Cell Lymphoma	Mitchell Reed Smith	Brian Gerald Till		Phase II	ECOG-ACRIN Cancer Research Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Supportive care, Treatment	 60 and over	 E1411, NCI-2011-02980, CDR0000707057, ECOG-E1411, NCT01415752	Lymphoma
99	Fred Hutch	Scleroderma Treatment with Autologous Transplant (STAT) Study	George Earl Georges	Bernadette A McLaughlin		Phase II	Fred Hutchinson Cancer Research Center; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 0 to 69	 2533.00, NCI-2011-01190, NCT01413100	N/A
100	Fred Hutch	High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma	Ajay Kumar Gopal	Ajay Kumar Gopal		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 18 and over	 2398.00, NCI-2011-01189, NCT01434472	Lymphoma
101	Fred Hutch	Trial of pIL-12 Electroporation Malignant Melanoma	Shailender Bhatia	Shailender Bhatia		Phase II	OncoSec Medical Inc	Pharma	 Treatment	 18 and over	 OMS-I100, NCI-2014-01065, 11854, NCT01502293	Melanoma
102	Fred Hutch	Combination Chemotherapy with or without Autologous Stem Cell Transplant in Treating Patients with Central Nervous System B-cell Lymphoma	Tracy T. Batchelor	Maciej Michal Mrugala		Phase II	Alliance for Clinical Trials in Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Supportive care, Treatment	 18 to 70	 CALGB 51101, NCI-2012-00110, CDR0000721927, NCT01511562	Lymphoma
103	Fred Hutch	Abiraterone Acetate in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer	Robert Bruce Montgomery	Robert Bruce Montgomery		Phase II	University of Washginton Medical Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 7639, NCI-2011-03745, 0801, NCT01508234, NCT01503229	Prostate; Mets
104	Fred Hutch	Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation	Marco Mielcarek	Marco Mielcarek		Phase II	Fred Hutchinson Cancer Research Center; NCI. National Heart Lung and Blood Institute	IIT; NCI; NHLBI	 Supportive care	 Not specified	 2545.00, NCI-2011-03827, NCT01525407	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
105	Fred Hutch	Donor Atorvastatin Treatment in Preventing Severe Acute GVHD after Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients with Hematological Malignancies	Marco Mielcarek	Marco Mielcarek		Phase II	Fred Hutchinson Cancer Research Center; NCI. National Heart Lung and Blood Institute	IIT; NCI; NHLBI	 Biomarker/Laboratory analysis, Supportive care	 0 to 75	 2546.00, NCI-2011-03828, NCT01527045	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
106	Fred Hutch	A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome	Vivian Gudrun Oehler	Vivian Gudrun Oehler		Phase II	Pfizer Inc	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 B1371003, NCI-2012-01145, 2012-000684-24, NCT01546038	Leukemia; Myelodysplastic Syndrome
107	Fred Hutch	A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer	Jennifer Marie Specht	Jennifer Marie Specht		Phase II	Hoffmann-La Roche	Pharma	 Treatment	 18 and over	 MO27782, NCI-2012-02068, 2011-003308-18, NCT01565083	Breast; Mets
108	Fred Hutch	Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer	Renato Goncalves Martins	Renato Goncalves Martins		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 18 and over	 7674, NCI-2012-00892, NCT01613768	Salivary Gland Cancer; Mets
109	Fred Hutch	Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer	Christina S Baik	Christina S Baik		Phase II	University of Washginton Medical Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 7755, NCI-2012-00865, NCT01620190	Lung
110	Fred Hutch	Donor Umbilical Cord Blood Transplant with or without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients with Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes	Colleen Delaney	Colleen Delaney		Phase II	Fred Hutchinson Cancer Research Center; NCI. National Heart Lung and Blood Institute	IIT; NCI; NHLBI	 Treatment	 6 to 45	 2603.00, NCI-2012-01572, 2603, NCT01690520	Leukemia; Myelodysplastic Syndrome
111	Fred Hutch	A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan and Evaluation of Combination DCDS4501A and Obinutuzumab in Patients With Non-Hodgkin's Lymphoma	Oliver W. Press	Oliver W. Press		Phase II	Genentech Inc.	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 GO27834, NCI-2013-00539, 2011-004377-84, NCT01691898	Lymphoma
112	Fred Hutch	Capecitabine and Celecoxib with or without Radiation Therapy in Treating Patients with Colorectal Cancer That Is Newly Diagnosed or Previously Treated with Fluorouracil	Edward H. Lin	Edward H. Lin		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 7707, NCI-2012-02137, NCT01729923	Colorectal
113	Fred Hutch	Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer	Elena Gabriela Chiorean	Elena Gabriela Chiorean		Phase II	Spectrum Pharmaceuticals Inc	Pharma	 Treatment	 18 and over	 SPI-1620-12-202, NCI-2013-01789, NCT01773785	Bile Duct
114	Fred Hutch	The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer	Celestia Savoye Higano	Celestia Savoye Higano		Phase II	Aragon Pharmaceuticals	Pharma	 Treatment	 18 and over	 CR103305, NCI-2013-01912, ARN-509-002, NCT01790126	Prostate
115	Fred Hutch	A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer	Robert Bruce Montgomery	Robert Bruce Montgomery		Phase II	Weill Medical College of Cornell University; Millennium Pharmaceuticals, Inc.	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 1210013164, NCI-2014-01689, NCT01799278	Prostate; Mets
116	Fred Hutch	A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies	Andrei R. Shustov	Andrei R. Shustov		Phase II	Gilead	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 GS-US-339-0102, NCI-2013-01283, NCT01799889	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
117	Fred Hutch	Tumor-Infiltrating Lymphocytes after Combination Chemotherapy in Treating Patients with Metastatic Melanoma	Sylvia Mina Lee	Sylvia Mina Lee		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 2643.00, NCI-2013-00486, NCT01807182	Melanoma; Mets
118	Fred Hutch	Chemotherapy in Treating Patients with Myelodysplastic Syndrome before Donor Stem Cell Transplant	Bart Lee Scott	Bart Lee Scott		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Supportive care, Treatment	 18 and over	 2661.00, NCI-2013-00538, 2661, NCT01812252	Myelodysplastic Syndrome
119	Fred Hutch	PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer	Sunil R Hingorani	Sunil R Hingorani		Phase II	Halozyme Therapeutics	Pharma	 Treatment	 18 and over	 HALO-109-202, NCI-2013-01369, NCT01839487	Pancreas; Mets
120	Fred Hutch	PF-04449913 in Treating Patients with Acute Leukemia or Myelodysplastic Syndromes at High Risk of Relapse after Donor Stem Cell Transplant	Daniel A. Pollyea	Vivian Gudrun Oehler		Phase II	University of Colorado Cancer Center - Anschutz Cancer Pavilion; NCI	NCI	 Treatment	 18 and over	 12-1558, NCI-2013-00824, 12-1558.cc, NCT01841333	Leukemia; Myelodysplastic Syndrome
121	Fred Hutch	Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children	Marie Bleakley	Marie Bleakley		Phase II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Supportive care	 21 and under	 2660.00, NCI-2013-00958, NCT01858740	Leukemia
122	Fred Hutch	CYT107 with or without Vaccine Therapy in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer	Lawrence Fong	Evan Ya-Wen Yu		Phase II	Cancer Immunotherapy Trials Network; NCI	Other; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 CITN12-03, NCI-2013-00998, CITN12-03 IL7, NCT01881867	Prostate; Mets
123	Fred Hutch	Treosulfan and Fludarabine Phosphate with or without Total Body Irradiation before Donor Stem Cell Transplant in Treating Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia	H. Joachim Deeg	H. Joachim Deeg		Phase II	Fred Hutchinson Cancer Research Center; NCI; National Heart Lung and Blood Institute	IIT; NCI; NHLBI	 Biomarker/Laboratory analysis, Treatment	 65 and under	 2524.00, NCI-2013-01261, 2524, NCT01894477	Leukemia; Myelodysplastic Syndrome
124	Fred Hutch	Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer	Hannah Margaret Linden	Hannah Margaret Linden		Phase II	University of Washington Medical Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 8093, NCI-2013-01326, NCT01908101	Breast; Mets
125	Fred Hutch	Chemotherapy, Stem Cell Transplant, and Romidepsin in Treating Patients with T-cell Non-Hodgkin Lymphoma	Steven Michael Horwitz,	Andrei R. Shustov		Phase II	Memorial Sloan-Kettering Cancer Center; NCI	NCI	 Treatment	 Over 16	 13-020, NCI-2013-01365, NCT01908777	Lymphoma
126	Fred Hutch	Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women	Hannah Margaret Linden	Hannah Margaret Linden		Phase II	Novartis Pharmaceuticals Corporation	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 CBYL719A2201, NCI-2014-00149, NCT01923168	Breast
127	Fred Hutch	Enzalutamide in Treating Patients with Metastatic, Castrate-Resistant Prostate Cancer	Mary-Ellen Taplin	Robert Bruce Montgomery		Phase II	Dana-Farber Harvard Cancer Center; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 13-301, NCI-2013-02258, NCT01942837	Prostate; Mets
128	Fred Hutch	Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)	Christina S Baik	Christina S Baik		Phase II	Millennium Pharmaceuticals, Inc.	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 C14018, NCI-2014-00808, 2013-003713-18, DRKS00007849, U1111-1154-9805, NCT02038647	Lung
129	Fred Hutch	Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL	Andrei R. Shustov	Andrei R. Shustov		Phase II	Spectrum Pharmaceuticals Inc	Pharma	 Supportive care	 18 and over	 SPI-FOL-14-201, NCI-2015-00888, NCT02106650	Lymphoma
130	Fred Hutch	Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer	Christina S Baik	Christina S Baik		Phase II	Incyte Corporation	Pharma	 Treatment	 18 to 75	 INCB 18424-266, NCI-2014-01067, NCT02119650	Lung
131	Fred Hutch	Gamma Secretase Inhibitor PF-03084014 in Treating Patients with AIDS-Associated Kaposi Sarcoma	Lee Ratner	Corey Casper		Phase II	AIDS - Associated Malignancies Clinical Trials Consortium; NCI	Other; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 AMC-089, NCI-2014-00638, NCT02137564	Sarcoma
132	Fred Hutch	S1406 Irinotecan Hydrochloride and Cetuximab with or without Vemurafenib in Treating Patients with Colorectal Cancer That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery	Edmund Scott Kopetz	Andrew Lawrence Coveler		Phase II	SWOG; NCI; Genentech Inc.	Coop Group; NCI; Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 S1406, NCI-2014-00814, NCT02164916	Colorectal; Mets
133	Fred Hutch	TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy	Christina S Baik	Christina S Baik		Phase II	Clovis Oncology	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 CO-1686-022 (TIGER-1), NCI-2014-02300, NCT02186301	Lung; Mets
134	Fred Hutch	Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas	Cristina Paguia Rodriguez	Cristina Paguia Rodriguez		Phase II	Karyopharm Therapeutics	Pharma	 Treatment	 18 and over	 KCP-330-006, NCI-2014-02188, NCT02213133	Head and Neck; Lung; Espophagus
135	Fred Hutch	An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma	Stephen Douglas Smith	Stephen Douglas Smith		Phase II	Acerta Pharma	Pharma	 Treatment	 18 and over	 ACE-LY-004, NCI-2015-00489, NCT02213926	Lymphoma
136	Fred Hutch	Selective Depletion of CD45RA+ Naive T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors for Prevention of GVHD	Marie Bleakley	Marie Bleakley		Phase II	Fred Hutchinson Cancer Research Center; National Heart Lung and Blood Institute; NCI	IIT; NCI; NHLBI	 Biomarker/Laboratory analysis, Treatment	 14 to 60	 2684.00, NCI-2014-01301, 2684, NCT02220985	Leukemia
137	Fred Hutch	A Phase 2, Multicenter Study in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma	Blythe Grace Thomson	Blythe Grace Thomson		Phase II	MedImmune Inc	Pharma	 Biomarker/Laboratory analysis, Treatment	 6 months to less than 18 years	 CD-ON-CAT-8015-1036, NCI-2014-01939, NCT02227108	Leukemia; Lymphoma
138	Fred Hutch	JAK-2 Inhibitor before Donor Stem Cell Transplant in Treating Patients with Primary or Secondary Myelofibrosis	Rachel B. Salit	Rachel B. Salit		Phase II	Fred Hutchinson Cancer Research Center; National Heart Lung and Blood Institute; NCI	IIT; NCI; NHLBI	 Biomarker/Laboratory analysis, Treatment	 7 months and over	 9033, NCI-2014-01882, FH9033, NCT02251821	Leukemia
139	Fred Hutch	Enzalutamide and Leuprolide Acetate with or without Abiraterone Acetate and Prednisone before Surgery in Treating Patients with Intermediate or High Risk Prostate Cancer Undergoing Prostatectomy	Mary-Ellen Taplin	Robert Bruce Montgomery		Phase II	Dana-Farber Harvard Cancer Center; NCI	NCI	 Treatment	 18 and over	 14-283, NCI-2014-02363, NCT02268175	Prostate
140	Fred Hutch	A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Christina S Baik	Christina S Baik		Phase II	F Hoffmann-La Roche Limited	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 BO29389, NCI-2014-02389, 2014-001237-83, NCT02289833	Lung; Mets
141	Fred Hutch	A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen	Michael Boeckh	Michael Boeckh		Phase II	Ansun BioPharma Inc	Pharma	 Treatment	 12 and over	 DAS181-2-05, NCI-2014-01331, NCT01644877	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
142	Fred Hutch	Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients with Stage IV Melanoma	Ramesh Rengan	Ramesh Rengan		Phase II	University of Washington Medical Center; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 9031, NCI-2013-01757, NCT01970527	Melanoma
143	Fred Hutch	Vitamin D and Calcium Carbonate with or without Pamidronate Disodium in Preventing Bone Loss in Younger Patients Who Have Undergone Stem Cell Transplant to Treat a Hematologic Malignancy	Anna Petryk	K. Scott Baker		Phase II	University of Minnesota Medical Center-Fairview; NCI	NCI	 Biomarker/Laboratory analysis, Supportive care	 1 to 17	 2013LS023, NCI-2014-02310, 1305M34621, CTSI 21472, MT2014-23R, NCT02074631	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
144	Fred Hutch	Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory Lymphoma	David G. Maloney	David G. Maloney		Phase I/II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 65 and under	 1409.00, NCI-2010-00130, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803	Lymphoma
145	Fred Hutch	Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis	George Earl Georges	George Earl Georges		Phase I/II	Fred Hutchinson Cancer Research Center; NCI; NIAID; Scleroderma Research Foundation	IIT; NCI; NIAID; Other	 Treatment	 17 to 70	 2067.00, NCI-2011-01352, FHCRC-2067.00, 6364, NCT00622895	N/A
146	Fred Hutch	Dose-Intensive Chemotherapy in Combination with Chemoprotected Autologous Stem Cells in Treating Patients with Malignant Gliomas	Hans-Peter Kiem	Hans-Peter Kiem		Phase I/II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 18 and over	 2000.00, NCI-2013-00701, 8357, FHCRC-2000.00, FHCRC-IR-6259, NCT00669669	Brain
147	Fred Hutch	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients with Hematologic Cancer	Brenda M. Sandmaier	Brenda M. Sandmaier		Phase I/II	Fred Hutchinson Cancer Research Center; NCI; Wayne D. Kuni and Joan E. Kuni Foundation	IIT; NCI; Other	 Treatment	 Any age	 2230.00, NCI-2010-00106, FHCRC-2230.00, IR-6771, NCT00789776	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
148	Fred Hutch	Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies	William I. Bensinger	William I. Bensinger		Phase I/II	Sanofi Aventis	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 TED10893, NCI-2010-02332, U1111-1116-5472, NCT01084252	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
149	Fred Hutch	A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma	William I. Bensinger	William I. Bensinger		Phase I/II	Academic Myeloma Consortium; Celgene Corporation; Onyx Pharmaceuticals Inc: Criterium Inc	Pharma; Other	 Treatment	 18 and over	 AMyC 10-MM-01, NCI-2012-01279, IST-CAR-521, PO-MM-PI-0034, NCT01464034	Myeloma
150	Fred Hutch	Temozolomide and Pazopanib Hydrochloride in Treating Patients with Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery	Halla S. Nimeiri	Elena Gabriela Chiorean		Phase I/II	Northwestern University; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 NU 11I03, NCI-2011-02939, NCT01465659	Pancreas
151	Fred Hutch	Dovitinib Lactate in Combination With Anastrozole, Exemestane, or Letrozole in Treating Patients With Hormone-Receptor Positive Metastatic Breast Cancer	Claudine Isaacs	Pia M. Herbolsheimer		Phase I/II	MedStar Georgetown University Hospital; NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 2010-535, NCI-2013-00749, NCT01484041	Breast; Mets
152	Fred Hutch	Alpha 1 Anti-Trypsin in Treating Patients with Acute Graft-Versus-Host Disease	H. Joachim Deeg	H. Joachim Deeg		Phase I/II	Fred Hutchinson Cancer Research Center; NCI; National Health Lung and Blood Institute	IIT; NCI; NHLBI	 Biomarker/Laboratory analysis, Supportive care	 not specified	 2571.00, NCI-2011-03805, 2571, NCT01523821	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
153	Fred Hutch	Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients	Christina S Baik	Christina S Baik		Phase I/II	Clovis Oncology	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 CO-1686-008, NCI-2012-00742, NCT01526928	Lung
154	Fred Hutch	Leukemia; Myelodysplastic Syndromes	Daniel Egan	Daniel Egan		Phase I/II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 Not specified	 2498.00, NCI-2011-03362, NCT01640301	Leukemia; Myelodysplastic Syndromes
155	Fred Hutch	Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	Anna Halpern	Anna Halpern		Phase I/II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 to 75	 2652.00, NCI-2012-02224, 2652, NCT01729845	Leukemia; Myelodysplastic Syndromes
156	Fred Hutch	Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant	Brenda M. Sandmaier	Brenda M. Sandmaier		Phase I/II	Bellicum Pharmaceuticals Inc	Pharma	 Treatment	 18 to 65	 BP-HM-001, NCI-2013-00518, NCT01744223	Leukemia; Lymphoma
157	Fred Hutch	Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors	Sarah E. Sherr Leary	Sarah E. Sherr Leary		Phase I/II	Sanofi Aventis	Pharma	 Biomarker/Laboratory analysis, Treatment	 2 to 18	 TED12689, NCI-2014-00195, U1111-1128-5704, NCT01751308	Peds; Solid Tumors; CNS
158	Fred Hutch	Viral oncoprotein targeted autologous T cell therapy for Merkel cell carcinoma	Aude Chapuis	Aude Chapuis		Phase I/II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 2586.00, NCI-2012-02779, 2586, NCT01758458	Skin
159	Fred Hutch	Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes	Bart Lee Scott	Bart Lee Scott		Phase I/II	Celgene Corporation	Phatma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 CC-486-AML-002, NCI-2013-01352, NCT01835587	Leukemia; Myelodysplastic Syndromes
160	Fred Hutch	Laboratory Treated T Cells in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia	David G. Maloney	David G. Maloney		Phase I/II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 2639.00, NCI-2013-00073, 2639, NCT01865617	Leukemia; Lymphoma
161	Fred Hutch	Radiolabeled Monoclonal Antibody and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with High-Risk Lymphoid Malignancies	Ajay Kumar Gopal	Ajay Kumar Gopal		Phase I/II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 2728.00, NCI-2013-01378, NCT01921387	Lymphoma
162	Fred Hutch	Vaccine Therapy with or without Polysaccharide-K in Treating Patients with Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy	Lupe G. Salazar	Lupe G. Salazar		Phase I/II	University of Washington Medical Center; Office of Cancer Complementary and Alternative Medicine; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 7866, NCI-2013-01377, 135, 7866/135, NCT01922921	Breast
163	Fred Hutch	Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients with Bladder Cancer	Robert Bruce Montgomery	Robert Bruce Montgomery		Phase I/II	University of Washington Medical Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 8027, NCI-2013-01614, NCT01938573	Bladder
164	Fred Hutch	ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma	William I. Bensinger	William I. Bensinger		Phase I/II	Acetylon Pharmaceuticals	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 ACE-MM-102, NCI-2014-00978, NCT01997840	Myeloma
165	Fred Hutch	A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer	Sylvia Mina Lee	Sylvia Mina Lee		Phase I/II	MedImmune Inc	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 D4190C00006, NCI-2013-02416, NCT02000947	Lung
166	Fred Hutch	A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)	Renato Goncalves Martins	Renato Goncalves Martins		Phase I/II	Merck and Company Inc	Pharma	 Treatment	 18 to 75	 3475-021, NCI-2014-00482, NCT02039674	Lung
167	Fred Hutch	Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes	Roland Bruno Walter	Roland Bruno Walter		Phase I/II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Treatment	 18 and over	 2734.00, NCI-2013-02465, 2734, NCT02044796	Leukemia; Myelodysplastic Syndromes
168	Fred Hutch	Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia	Edward Norton Libby	Edward Norton Libby		Phase I/II	Idera Pharmaceuticals, Inc.	Pharma	 Treatment	 18 and over	 8400-401, NCI-2014-00988, NCT02092909	Lymphoma
169	Fred Hutch	Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma	Ajay Kumar Gopal	Ajay Kumar Gopal		Phase I/II	University of Washington Medical Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 9111, NCI-2014-01782, NCT02227199	Lymphoma
170	Fred Hutch	ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies	Stephen Douglas Smith	Stephen Douglas Smith		Phase I/II	Acerta Pharma	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 ACE-LY-001, NCI-2015-00533, NCT02328014	Lymphoma
171	Fred Hutch	Genetically Modified T Cells in Treating Patients with Stage III-IV Non-small Cell Lung Cancer or Mesothelioma	Sylvia Mina Lee	Sylvia Mina Lee		Phase I/II	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 2727.00, NCI-2015-00329, 2727, NCT02408016	Lung; Mesothelioma
172	Fred Hutch	Everolimus in Treating Patients with Kidney Cancer Who Have Undergone Surgery	Christopher W. Ryan	Scott S. Tykodi		Phase III	SWOG; NCI	Coop Group; NCI	 Tissue collection/Repository, Treatment	 18 and over	 S0931, NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249	Kidney
173	Fred Hutch	Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery	Sang Young Ryu	Heidi Joy Gray		Phase III	Gynecologic Oncology Group; NCI	Coop Group; NCI	 Tissue collection/Repository, Treatment	 18 and over	 GOG-0263, NCI-2011-02037, CDR0000670125, NCT01101451	Cervix
174	Fred Hutch	Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery	Jeffrey A. Meyerhardt	Elena Gabriela Chiorean		Phase III	Alliance for Clinical Trials in Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 CALGB 80702, NCI-2011-02050, CALGB/SWOG 80702, CALGB-SWOG C80702, CDR0000675693, NCT01150045	Colorectal
175	Fred Hutch	Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)	Barbara Ann Goff	Barbara Ann Goff		Phase III	Endocyte Inc	Pharma	 Treatment	 18 and over	 8109-002, NCI-2011-00940, EC-FV-06, NCT01170650	Ovary
176	Fred Hutch	Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy	David G. Maloney	David G. Maloney		Phase III	GlaxoSmithKline	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 113676, NCI-2012-01195, NCT01200589	Lymphoma
177	Fred Hutch	Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma	Paul Gerard Guy Richardson	William I. Bensinger		Phase III	Dana-Farber Harvard Cancer Center; NCI	NCI	 Treatment	 18 to 65	 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662	Myeloma
178	Fred Hutch	Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	Brenda M. Sandmaier	Brenda M. Sandmaier		Phase III	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Supportive care, Treatment	 not specified	 2448.00, NCI-2010-02035, NCT01231412	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
179	Fred Hutch	Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer	Kevin Michael Kalinsky	Julie Ruth Gralow		Phase III	NCI	NCI	 Health services research, Treatment	 18 and over	 S1007, NCI-2011-02623, CDR0000692475, SWOG-S1007, NCT01272037	Breast
180	Fred Hutch	Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer	William Proctor Harris	William Proctor Harris		Phase III	BTG International Inc	Pharma	 Treatment	 18 and over	 TS-102, NCI-2012-00575, NCT01483027	Colorectal; Mets
181	Fred Hutch	Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Patients with Early-Stage Breast Cancer	Dawn Lauryn Hershman	Julie Ruth Gralow		Phase III	SWOG; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Supportive care	 Postmenopausal	 S1200, NCI-2012-00251, CDR0000725249, SWOG-S1200, NCT01535066	Breast
182	Fred Hutch	Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer	William Proctor Harris	William Proctor Harris		Phase III	BTG International Inc	Pharma	 Treatment	 18 and over	 TS-103, NCI-2012-01029, NCT01556490	Liver
183	Fred Hutch	A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma	William I. Bensinger	William I. Bensinger		Phase III	Millennium Pharmaceuticals, Inc.	Pharma	 Treatment	 18 and over	 C16010, NCI-2013-00086, 2011-005496-17, CTR20130908, NCT01564537	Myeloma
184	Fred Hutch	The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)	Bart Lee Scott	Bart Lee Scott		Phase III	Celgene Corporation	Pharma	 Supportive care	 18 and over	 AZA-MDS-003, NCI-2013-00382, 2012-002471-34, NCT01566695	Myelodysplastic Syndrome
185	Fred Hutch	INSPIRE: Internet and Social-media Program with Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant	Karen L Syrjala	Karen L Syrjala		Phase III	Fred Hutchinson Cancer Research Center; NCI	IIT; NCI	 Supportive care	 18 and over	 2605.00, NCI-2012-00743, NCT01602211	Any
186	Fred Hutch	Proton Beam or Intensity-Modulated Radiation Therapy in Treating Patients with Low or Low-Intermediate Risk Prostate Cancer	Jason Alexander Efstathiou	Jing Zeng		Phase III	Dana-Farber Harvard Cancer Center; NCI	NCI	 Biomarker/Laboratory analysis, Supportive care, Treatment	 18 and over	 11-497, NCI-2012-01144, NCT01617161	Prostate
187	Fred Hutch	Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer	Mariana Chavez-MacGregor	Julie Ruth Gralow		Phase III	SWOG; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 S1207, NCI-2012-01995, CDR0000738280, SWOG-S1207, NCT01674140	Breast
188	Fred Hutch	Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma	Ajay Kumar Gopal	Ajay Kumar Gopal		Phase III	Millennium Pharmaceuticals, Inc.; Seattle Genetics	Pharma	 Treatment	 18 and over	 C25003, NCI-2012-03101, 12/LO/1950, 2011-005450-60, JapicCTI-142491, U1111-1161-4937, NCT01712490	Lymphoma
189	Fred Hutch	An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)	John Michael Pagel	John Michael Pagel		Phase III	Janssen Pharmaceuticals	Pharma	 Treatment	 65 and over	 PCYC-1116-CA, NCI-2013-01129, 2012-003968-44, NCT01724346	Leukemia; Lymphoma
190	Fred Hutch	Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL	Andrei R. Shustov	Andrei R. Shustov		Phase III	Kyowa Hakko Kirin Pharma, Inc.	Pharma	 Treatment	 18 and over	 0761-010, NCI-2012-02782, NCT01728805	Lymphoma
191	Fred Hutch	Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy	William Proctor Harris	William Proctor Harris		Phase III	Daiichi Sankyo Inc; Covance; ArQule	Pharma	 Treatment	 18 and over	 ARQ197-A-U303, NCI-2013-00021, NCT01755767	Liver
192	Fred Hutch	A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma	William Proctor Harris	William Proctor Harris		Phase III	Eisai Inc	Pharma	 Treatment	 18 and over	 E7080-G000-304, NCI-2013-02335, NCT01761266	Liver
193	Fred Hutch	A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer	Andrew L Coveler	Andrew L Coveler		Phase III	XBiotech USA	Pharma	 Supportive care	 18 and over	 2012-PT023, NCI-2013-00997, NCT01767857	Colorectal
194	Fred Hutch	Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer	Neeraj Agarwal	Heather H. Cheng		Phase III	SWOG; NCI	Coop Group; NCI	 Treatment	 18 and over	 S1216, NCI-2012-02876, SWOG-S1216, NCT01809691	Prostate; Mets
195	Fred Hutch	Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer	Andrew L Coveler	Andrew L Coveler		Phase III	NewLink Genetics Corporation	Pharma	 Treatment	 18 and over	 NLG0505, NCI-2013-01044, 1210-1195, NCT01836432	Pancreas
196	Fred Hutch	Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib	William Proctor Harris	William Proctor Harris		Phase III	Exelixis Inc	Pharma	 Treatment	 18 and over	 XL184-309, NCI-2013-02092, NCT01908426	Liver
197	Fred Hutch	A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer	Celestia Savoye Higano	Celestia Savoye Higano		Phase III	Aragon Pharmaceuticals, Inc.	Pharma	 Biomarker/Laboratory analysis, Treatment	 18 and over	 CR102931, NCI-2013-02187, 2012-004322-24, ARN-509-003, NCT01946204	Prostate
198	Fred Hutch	A Study of the Efficacy and Safety of Nivolumab vs Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients at Different Stages of Treatment (CheckMate 143)	Marc Charles Chamberlain	Marc Charles Chamberlain		Phase III	Bristol-Myers Squibb	Pharma	 Treatment	 18 and over	 CA209-143, NCI-2014-00328, 2013-003738-34, NCT02017717	Brain
199	Fred Hutch	Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Tait D. Shanafelt	Mazyar Shadman		Phase III	National Cancer Institute	NCI	 Biomarker/Laboratory analysis, Treatment	 18 to 70	 E1912, NCI-2014-00118, ECOG-E1912, NCT02048813	Leukemia; Lymphoma
200	Fred Hutch	Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)	Elena Gabriela Chiorean	Elena Gabriela Chiorean		Phase III	Incyte Corporation	Pharma	 Treatment	 18 and over	 INCB 18424-362, NCI-2014-01324, NCT02117479	Pancreas
201	Fred Hutch	Erlotinib Hydrochloride in Treating Patients with Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)	Ramaswamy Govindan	Rafael Santana-Davila		Phase III	National Cancer Institute	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 A081105, NCI-2014-01508, NCT02193282	Lung
202	Fred Hutch	Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)	David Eric Gerber	Rafael Santana-Davila		Phase III	ECOG-ACRIN Cancer Research Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 E4512, NCI-2014-01507, NCT02201992	Lung
203	Fred Hutch	Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study	Ann Elizabeth Woolfrey	Ann Elizabeth Woolfrey		Phase III	Jazz Pharmaceuticals plc	Pharma	 Treatment	 Not specified	 P2006-05, NCI-2009-01678, NCT00628498	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
204	Fred Hutch	Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A	Michael Boeckh	Michael Boeckh		Phase III	GlaxoSmithKline	Pharma	 Prevention	 18 and over	 115523, NCI-2013-00630, 2012-000138-20, NCT01610414	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
205	Fred Hutch	A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients	Michael Boeckh	Michael Boeckh		Phase III	Chimerix, Inc.	Pharma	 Prevention	 18 and over	 115523, NCI-2013-00630, 2012-000138-20, NCT01610414	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
206	Fred Hutch	A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)	Michael Boeckh	Michael Boeckh		Phase III	Vical Inc	Pharma	 Prevention	 18 and over	 115523, NCI-2013-00630, 2012-000138-20, NCT01610414	Leukemia; Lymphoma; Myelodysplastic Syndrome
207	Fred Hutch	Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis	H. Joachim Deeg	H. Joachim Deeg		Phase III	Gilead	Pharma	 Treatment	 18 and over	 GS-US-352-0101, NCI-2013-02398, 2013-002707-33, NCT01969838	Leukemia
208	Fred Hutch	MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)	Margaret Green	Margaret Green		Phase III	Merck and Company Inc	Pharma	 Supportive care	 18 and over	 8228-001, NCI-2014-01367, 2013-003831-31, NCT02137772	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
209	Fred Hutch	Paclitaxel and Carboplatin with or without Metformin Hydrochloride in Treating Patients with Stage III, IV, or Recurrent Endometrial Cancer	Victoria Lin Bae-Jump	Heidi Joy Gray		Phase II/III	NRG Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 GOG-0286B, NCI-2013-02284, NCT02065687	Endometrius
210	Fred Hutch	Trametinib in Treating Patients with Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	David M. Gershenson	Heidi Joy Gray		Phase II/III	National Cancer Institute	NCI	 Biomarker/Laboratory analysis, Treatment	 19 and over	 GOG-0281, NCI-2014-00629, NCT02101788	Ovary; Primary Peritoneal
211	Fred Hutch	Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer	Vassiliki A. Papadimitrakopoulou	Christina S Baik		Phase II/III	SWOG; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 S1400, NCI-2014-00627, S1400A, S1400B, S1400C, S1400D, S1400E, NCT02154490	Lung
212	Fred Hutch	An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol	John A. Thompson	John A. Thompson		Phase IV	Hoffmann-La Roche	Pharma	 Treatment	 18 and over	 GO28399, NCI-2013-01160, 2012-003144-80, NCT01739764	Any
213	NSHS-Children's	Genetic Biomarkers in Children With Neuroblastoma (also known as Neuroblastoma Epidemiology in North America [NENA])	Andrew F. Olshan	Andrew F. Olshan		No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Natural history/Epidemiology	 Children under 18 years old and parents	 AEPI07N1, NCI-2011-02257, CDR0000594334, COG-AEPI07N1, NCT01119560	CNS
214	NSHS-Children's	Study of Blood Samples From Newborns With Down Syndrome	April Deon Sorrell	Arlene Sara Redner, MD	119	No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis	 Under 90 days at diagnosis	 AAML08B1, NCI-2011-02193, CDR0000636115, COG-AAML08B1, NCT00959283	N/A
215	NSHS-Children's	Informed Consent to Enroll Younger Patients with Newly Diagnosed Cancer in the Childhood Cancer Research Network	Julie Ross	Arlene Sara Redner, MD	119	No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Health services research, Treatment	 18 and under	 ACCRN07, NCI-2009-00331, 10-C-0111, CDR0000069496, NCT01117168	Peds
216	NSHS-Children's	Study of Kidney Tumors in Younger Patients	Elizabeth Anne Mullen	Arlene Sara Redner, MD	119	No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Natural history/Epidemiology, Tissue collection/Repository	 Under 30	 AREN03B2, NCI-2009-00416, CDR0000459797, COG-AREN03B2, NCT00898365	Kidney
217	NSHS-Children's	Biomarkers in Tumor Tissue Samples from Patients with Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma	Michael D. Hogarty	Arlene Sara Redner, MD	119	No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Tissue collection/Repository	 Under 31	 ANBL00B1, NCI-2009-00397, CDR0000078642, NCT00256763, COG-ANBL00B1, NCT00904241	CNS
218	NSHS-Children's	Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma	Steve Skapek	Arlene Sara Redner, MD	119	No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Tissue collection/Repository	 50 and under	 D9902, NCI-2009-00502, CCG-B904, CDR0000078602, COG-D9902, IRS-D9902, POG-9153, NCT00919269	Sarcoma
219	NSHS-Children's	Risk-Based Classification System of Patients with Newly Diagnosed Acute Lymphoblastic Leukemia	Karen Ruth Rabin	Arlene Sara Redner, MD	119	No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Health services research, Tissue collection/Repository	 30 and under	 AALL08B1, NCI-2011-02235, CDR0000674844, COG-AALL08B1, NCT01142427	Leukemia
220	NSHS-Children's	Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples from Young Patients With Cancer	Nilsa C. Ramirez	Arlene Sara Redner, MD	119	No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Tissue collection/Repository	 0 months to 30 year	 ABTR01B1, NCI-2009-00324, CDR0000271415, COG-ABTR01B1, NCT00898079	Peds
221	NSHS-Children's	Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma	Richard G. Gorlick	Arlene Sara Redner, MD	119	No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Tissue collection/Repository	 No age limitations	 AOST06B1, NCI-2009-00410, CDR0000562538, COG-AOST06B1, NCT00899275	Sarcoma
222	NSHS-Children's	Collecting and Storing Biological Samples From Patients With Ewing Sarcoma	Stephen L. Lessnick	Carolyn Fein Levy, MD	91	No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Tissue collection/Repository	 21 and under	 AEWS07B1, NCI-2009-00370, CDR0000544202, COG-AEWS07B1, NCT00899990	Sarcoma
223	Feinstein Institute	A Pharmacologic Study of Arsenic Trioxide in Cancer Patients		Cristina Ghiuzeli, MD	108	No phase specified			Biomarker/Laboratory Analysis?	18 or older	10-326A	Any
224	Feinstein Institute	Extension Study of Trastuzamab Emtansine as a Single Agent or in Combination with Other Therapies in Patients Previously Enrolled in a Genentech and/or F.Hoffman-LARoche LTD-Sponsored Trastuzamab Emtansine Study		Daniel Budman, MD	62	No phase specified			Treatment		14-06-263-03	Breast
225	NSLIJ 	Breast-Conserving Surgery and Radiation Therapy in Treating Patients with Multiple Ipsilateral Breast Cancer	Judy C. Szemere Boughey	Dominic Filiardi, MD		No phase specified	Alliance for Clinical Trials in Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 40 and over	 Z11102, NCI-2012-00707, ACOSOG-Z11102, CDR0000728605, NCT01556243	Breast
226	Feinstein Institute	Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)		Dominic Filiardi, MD		No phase specified			Health Services Research, Treatment	female 40 years of age or older	14-086B	Breast
227	Feinstein Institute	Chemotherapy plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck		Doru Paul, MD	109	No phase specified			Treatment	18 years of age or older	13-06-304-03	Head & Neck
228	Feinstein Institute	A Pilot Study Treatment of Malignant Tumors using [18F] Fluorodeoxyglucose (FDG)		Doru Paul, MD	109	No phase specified			Treatment	21 years of age or older	13-382	Lymphoma; Solid Tumors
229	Feinstein Institute	Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)		Doru Paul, MD	109	No phase specified			Treatment	18 years of age or older	14-06-320-03	Lung
230	Feinstein Institute	Blood Stem Cell with Marrow Transplantation Study		Indira Sahdev, MD	114	No phase specified			Treatment?		03-155	UNK
231	Feinstein Institute	Allogeneic HSCT in Pediatric Solid Tumors and Lymphomas 		Indira Shadev, MD	114	No phase specified			Treatment?		05-016T	Lymphoma; Solid Tumors?
232	Feinstein Institute	An Extension Study to Investigate the Safety and Durability of Clinical Activity of CAL-101 in Patients with Hematologic Malignancies		Jacqueline Barrientos, MD	139	No phase specified			Treatment	18 or older	12-06-59-03	Leukemia; Lymphoma; Myeloma
233	NSLIJ	Compliance Rate of Delayed Oophorectomy in Patients with BRCA Gene Mutation Undergoing Salpingectomy	Denise Renee Nebgen	Jean A. Hurteau, MD	211	No phase specified	MD Anderson; NCI	IIT; NCI	 Prevention, Screening	 35 to 46	 2013-0340, NCI-2015-00465, NCT01907789	Breast; Ovary
234	Feinstein Institute	Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients with Hematological Malignancies		Joel A. Brochstein, MD	117	No phase specified			Treatment	at least 12 years of age	14-10-84-06A	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
235	NSHS-Children's	Effects of Dexrazoxane Hydrochloride on Biomarkers Associated with Cardiomyopathy and Heart Failure after Cancer Treatment	Eric J. Chow	Jonathan Fish, MD	116	No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Natural history/Epidemiology	 Not specified	 ALTE11C2, NCI-2012-03196, S0004187, NCT01790152	Peds
236	Feinstein Institute	Health Effects after Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-related Cardiomyopathy		Jonathan Fish, MD	116	No phase specified			Health Services Research, Natural History/Epidemiology?		E14-105	Any
237	Feinstein Institute	Randomized Controlled Study of Neurocognitive Outcomes in Patients with Five or More Brain Metastases Treated with Radiosurgery or Whole Brain Radiotherapy		Jonathan Knisely, MD	175	No phase specified			Behavioral Study, Treatment	18 years of age or older	14-059A	Brain; Mets
238	Feinstein Institute	Evaluation of Time Delayed magnetic Resonance Imaging using a High Relaxivity Agent to Improve Detection of Brain Metastatic Disease		Jonathan Knisely, MD	175	No phase specified			Screening?	18 or older	11-356A	Brain; Mets
239	Feinstein Institute	Comparing Single Cell Network Profiling (SCNP) Signaling Readouts in Fresh vs. Cryopreserved Aliquots from Bone Marrow (BM) and/or Peripheral Blood (PB) Samples Collected at Time of Diagnosis from Patients with non-M3 Acute Myeloid Leukemia (AML)		Jonathan Kolitz, MD	67	No phase specified			Biomarker/Laboratory Analysis	18 or older	12-112B	Leukemia
240	LIJ	Study of Biomarkers in Blood and Bone Marrow Samples from Patients with Previously Untreated Chronic Lymphocytic Leukemia	John C. Byrd	Kanti Rai, MD	76	No phase specified	Alliance for Clinical Trials in Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis	 Not specified	 CALGB 20203, NCI-2009-00458, CDR0000398201, NCT01005368	Leukemia
241	NSLIJ 	Study of Biomarkers in Blood and Bone Marrow Samples from Patients with Previously Untreated Chronic Lymphocytic Leukemia	John C. Byrd	Kanti Rai, MD	76	No phase specified	Alliance for Clinical Trials in Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis	 Not specified	 CALGB 20203, NCI-2009-00458, CDR000	Leukemia
242	Feinstein Institute	Chronic Lymphocytic Leukemia - Tissue Collection Study 		Kanti Rai, MD	76	No phase specified	Chronic Lymphocytic Leukemia Research Consortium (CRC)	Coop Group; NCI	Tissue collection/Repository		04.04.012T	Leukemia
243	Feinstein Institute	Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer 		Lora Weiselberg, MD	104	No phase specified			Treatment	female or male 18 years of age or older	E14-412	Breast
244	Feinstein Institute	The Men’s Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance		Manish Vira, MD	184	No phase specified			Public health intervention	between the ages of 50 and 80	11-333B	Prostate
245	Feinstein Institute	Brain Tumor - Tissue Donation Study		Marc Symons, PhD	83	No phase specified	North Shore-LIJ Heath System	IIT	Tissue collection/Repository		06-086	Brain
246	Feinstein Institute	Assessment of Overall Survival of FOLFOX6m plus SIR-Spheres® microspheres versus FOLFOX6m alone as first-line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma in a randomised clinical study		Mark A. Westcott, MD		No phase specified			Treatment	18 years or older	20130019	Colorectal; Liver; Mets
247	NSHS-Children's	Neuropsychological and Behavioral Testing in Younger Patients with Cancer	Leanne M. Embry	Mark P. Atlas, MD	129	No phase specified	Children's Oncology Group; NCI	Coop Group; NCI	 Natural history/Epidemiology	 3 to 21	 ALTE07C1, NCI-2009-00383, CDR0000594326, COG-ALTE07C1, NCT00772200	Peds
248	Feinstein Institute	Glioblastoma-Adults 		Michael Schulder, MD	77	No phase specified			?	at least 18 years of age, man or woman 	Protocol 100-200 (12-06-109)	Brain
249	NSLIJ	Changes in Brain Function in Patients with Breast Cancer or Lymphoma Receiving Chemotherapy	Michelle C. Janelsins	Michelle C. Janelsins		No phase specified	University of Rochester NCORP Research Base; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Supportive care	 Not specified	 URCC10055, NCI-2011-02878, 10055, CDR0000697582, NCT01382082	Breast; Lymphoma
250	Feinstein Institute	Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults- City of Hope		Myra Barginear, MD	143	No phase specified			Biomarker/Laboratory Analysis	at least 65 or older	13-157	Breast
251	Feinstein Institute	Prospective Registry of MammaPrint in breast cancer patients with an Intermediate recurrence Score (PROMIS)		Myra Barginear, MD	143	No phase specified			Registry	18 or older	12-06-379-03	Breast
252	Feinstein Institute	Human Blood Cell Disorders Tissue Bank		Nicholas Chiorazzi, MD	63	No phase specified			Tissue collection/Repository		08-202	Leukemia; Lymphoma; Myeloma; Myelodysplastic Syndrome
253	NSHS-Children's	Long-Term Effects of Cancer Therapy in Patients With Wilms' Tumor	Wendy Leisenring	Norman Breslow		No phase specified	National Wilms Tumor Study Group; NCI	Coop Group; NCI	 Natural history/Epidemiology	 18 to 85	 COG-4941L, NCI-2009-00715, CDR0000069131, IRB00024842, Q9403, NCT00228696	Kidney
254	Feinstein Institute	A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications		Ruthee-Lu Bayer, MD	97	No phase specified			Health Services Research?		11-230A	Leukemia; Lymphoma; Myeloma
255	Feinstein Institute	Autologous Stem Cell Transplant with Pomalidomide (CC-4047) Maintenance vs Continuous Clarithromycin/ Pomalidomide/ Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma		Ruthee-Lu Bayer, MD	97	No phase specified			Treatment	18 years or older	13-093B	Multiple Myeloma
256	Feinstein Institute	PNH Registry		Steven Allen, MD	60	No phase specified			Registry		07-08-259-03	UNK
257	Feinstein Institute	Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?		Veena Susan John, MD	95	No phase specified			Public health intervention	18 or older	12-330B	Ovary; Fallopian; Primary Peritoneal
258	Feinstein Institute	Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer		Veena Susan John, MD	95	No phase specified			Treatment	18 or older	08-150A	Ovary; Fallopian; Primary Peritoneal
259	Feinstein Institute	A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus		Veena Susan John, MD	95	No phase specified			Treatment	18 or older	10-175B	Uterus
260	LIJ; NSLIJ	Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients with Stage I-III Breast Cancer	Vered Stearns	Vincent Vinciguerra, MD	85	No phase specified	ECOG-ACRIN Cancer Research Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Supportive care	 18 and over	 E1Z11, NCI-2013-00426, ECOG-E1Z11, NCT01824836	Breast
261	Feinstein Institute	A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)		Vincent Vinciguerra, MD	85	No phase specified			Natrual History/Epidemiology		13-605A	Breast
262	Feinstein Institute	Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-Treatment, Post-Treatment and at Six Month Follow-up 		Vincent Vinciguerra, MD	85	No phase specified			Supportive Care, Behavioral Study	21 or older	11-196A	Breast; Lymphoma
263	Cold Spring Harbor	PEGPH20 and Cetuximab before Surgery in Treating Patients with Pancreatic Cancer That Can Be Removed by Surgery	Kenneth Ho-Ming Yu	David Tuveson, MD, PhD	31	No phase specified	Memorial Sloan-Kettering Cancer Center; NCI	IIT; NCI	Diagnostic, Treatment	18 and over	14-039, NCI-2014-01977, NCT02241187	Pancreas
264	Fred Hutch	A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)	Laura Q.M. Chow	Laura Q.M. Chow		No phase specified	Pfizer Inc; Merck and Company Inc	Pharma	Treatment			Solid Tumor; Mets
265	Feinstein Institute	An Open Label, First-in-Human Study of the Safety, Tolerability and Pharmacokinetics of VX-970 in Combination with Cytotoxic Chemotherapy in Subjects with Advanced Solid Tumors		Craig Devoe, MD	99	Phase I			Treatment	18 years or older	13-06-337Q-03N	Solid Tumors
266	Feinstein Institute	Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Temozolomide (Temodar) for Treatment of Newly Diagnosed Glioblastoma Multiforme and Anaplastic Astrocytoma		John Boockvar, MD	189	Phase I			Treatment	18 years of age or older	14-292A	Brain
267	Feinstein Institute	Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma		John Boockvar, MD	189	Phase I			Treatment	18 years of age of older	14-712	Brain
268	Feinstein Institute	Phase I Trial of Super-Selective Intra-Arterial Infusion of Cetuximab (Erbitux) with or without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck		John Boockvar, MD	189	Phase I			Treatment	18 years of age or older	15-182	Head & Neck
269	Feinstein Institute	Phase I Study of Stereotactic Body Radiation Therapy (SBRT) For Organ Confined Prostate Cancer		Louis Potters, MD	75	Phase I			Treatment	18 and older	10-128B	Prostate
270	Feinstein Institute	A Phase I Trial of IMRT with Dose-Escalated Image-Guided Stereotactic Radiosurgery (SRS) Boost for Human Papilloma Virus (HPV)-Unassociated Oropharyngeal Cancer		Maged Ghaly, MD	122	Phase I			Treatment	18 or older	09-309A	Head & Neck
271	NSHS-Children's	Lenalidomide and Radiation Therapy in Treating Younger Patients with Pontine Glioma or High-Grade Glioma	Katherine Elizabeth Warren	Mark P. Atlas, MD	129	Phase I	NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 21 and under	 10-C-0219, NCI-2011-02539, 100219, CDR0000687467, NCI-10-C-0219, NCT01226940, 8449, NCT01222754	Brain
272	Feinstein Institute	A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination with Rituximab in Subjects with Relapsed or Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma		Jacqueline Barrientos, MD	139	Phase I/II			Treatment	18 or older	12-06-203-06	Leukemia; Lymphoma
273	Feinstein Institute	Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme		John Boockvar, MD	189	Phase I/II			Treatment	18 years of age or older	14-352	Brain
274	Feinstein Institute	Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma		John Boockvar, MD	189	Phase I/II			Treatment	18 years of age or older	14-353	Brain
275	NSHS-SI	Bortezomib, Dexamethasone, and Lenalidomide with or without Elotuzumab in Treating Patients with Newly Diagnosed High-Risk Multiple Myeloma	Saad Zafar Usmani	Marcel Odaimi, MD	148	Phase I/II	SWOG; NCI	Coop Group; NCI	 Treatment	 18 and over	 S1211, NCI-2012-01998, CDR0000738512, PS1211_A12PAMDREVW01, SWOG-S1211, NCT01668719	Multiple Myeloma
276	Feinstein Institute	EMRI TRUS Fusion Guided Prostate Biopsy - An Improved Way to Detect and Quantify Prostate Cancer - A Phase II Study 		Ardeshir Rastinehad, DO		Phase II			Health Services Research, Screening	18 years of age or older	11-322A	Prostate
277	NSHS-Children's	Combination Chemotherapy with or without Ganitumab in Treating Patients with Newly Diagnosed Metastatic Ewing Sarcoma	Steven G. DuBois	Arlene Sara Redner, MD	119	Phase II	NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 50 and under	 AEWS1221, NCI-2014-02380, NCT02306161	Sarcoma
278	Feinstein Institute	A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo with FOLFIRI Second-Line Therapy in Patients with Metastatic Colorectal Cancer		Craig Devoe, MD	99	Phase II			Treatment	18 or older	13-050B	Colorectal
279	Feinstein Institute	A Phase 2, Randomized, Multicenter Study of PEGPH20 Combined with nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer		Craig Devoe, MD	99	Phase II			Treatment	18 or older	13-06-63-03N	Pancreas
280	LIJ	Combination Chemotherapy with or without Regorafenib in Treating Patients with Metastatic Colorectal Cancer	Hanna Kelly Sanoff	Craig Devoe, MD	99	Phase II	University of North Carolina at Chapel Hill; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 LCCC 1029, NCI-2013-00954, 10-2176, NCT01298570	Colorectal
281	NSLIJ 	Dabrafenib and Trametinib in Treating Patients with Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery	Alain Patrick Algazi	Craig Devoe, MD	99	Phase II	NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 S1320, NCI-2014-01470, NCT02196181	Melanoma
282	Feinstein Institute	A Multicenter, Open-Label, Phase 2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Relapsed/Refractory Marginal Zone Lymphoma		Jacqueline Barrientos, MD	139	Phase II			Treatment	man or woman 18 years of age or older	14-06-248	Lymphoma
283	Feinstein Institute	A Randomized Phase II Study of Ibrutinib (PCI-32765) Based Therapy vs. Standard Fludarabine, Cyclophosphamide and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)		Jacqueline Barrientos, MD	139	Phase II			Treatment	between the ages of 18 and 70	E14-324	Leukemia
284	Feinstein Institute	An Open-Label, Randomized, Phase 2, Parallel, Dose-Ranging, Multicenter, Study of Sotatercept for the Treatment of Patients with Anemia and Low or Intermediate-1 Risk Myelodysplastic Syndromes		Johnson Liu, MD	72	Phase II			Treatment	18 or older	12-06-342-03	Myelodysplastic Syndrome
285	Feinstein Institute	A Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation vs Bevacizumab Alone as Treatment for Recurrent Glioblastoma		Jonathan Knisely, MD	175	Phase II			Treatment	18 years of age or older	14-012A	Brain
286	NSLIJ; NSHS-SS	Bevacizumab with or without Radiation Therapy in Treating Patients with Recurrent Glioblastoma	Christina I. Tsien	Jonathan Knisely, MD	175	Phase II	NRG Oncology; NCI	Coop Group; NCI	 Treatment	 18 and over	 RTOG 1205, NCI-2012-01732, NCT01730950	Brain
287	LIJ	Vemurafenib in Treating Patients with Relapsed or Refractory Hairy Cell Leukemia	Jae Park	Kanti Rai, MD	76	Phase II	Memorial Sloan-Kettering Cancer Center; NCI	IIT; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 12-200, NCI-2012-02170, NCT01711632	Leukemia
288	LIJ	Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)	William George Wierda	Kanti Rai, MD	76	Phase II	MD Anderson Cancer Center; Celgene Corporation	IIT; Pharma	 Treatment	 18 and over	 2008-0385, NCI-2009-01510, Celgene # RV-CLL-PI-0223, NCT00628238	Leukemia
289	Feinstein Institute	A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients with Relapsed or Refractory Hairy Cell Leukemia		Kanti Rai, MD	76	Phase II			Treatment	man or woman 18 years of age or older	13-286B 	Leukemia
290	NSHS-Children's	Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma	Lucie E. Lafay-Cousin	Mark P. Atlas, MD	129	Phase II	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 47 months old or younger	 ACNS1221, NCI-2013-02379, COG-ACNS1221, NCT02017964	Brain
291	NSHS-Children's	Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors	Ute Katharina Bartels	Mark P. Atlas, MD	129	Phase II	Children's Oncology Group; NCI	Coop Group; NCI	 Supportive care, Treatment	 3 to 21	 ACNS1123, NCI-2012-01967, CDR0000734032, COG-ACNS1123, NCT01602666	CNS
292	NSHS-Children's	Temozolomide and Irinotecan Hydrochloride with or without Bevacizumab in Treating Young Patients with Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors	Adam Scott Levy	Mark P. Atlas, MD	129	Phase II	NCI	NCI	 Treatment	 21 and under	 ACNS0821, NCI-2011-02605, CDR0000686608, COG-ACNS0821, NCT01217437	CNS
293	NSLIJ 	Clarithromycin, Pomalidomide and Dexamethasone with or without Stem Cell Transplant in Treating Patients with Relapsed or Refractory Multiple Myeloma	Sergio Andres Giralt	Ruthee-Lu Bayer, MD	97	Phase II	Memorial Sloan-Kettering Cancer Center; NCI	IIT; NCI	 Treatment	 18 and over	 12-138, NCI-2012-02936, NCT01745588	Multiple Myeloma
294	Feinstein Institute	A Phase II Clinical Trial of Lenalidomide Intensification in Patients with Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance after Autologous Stem Cell Transplantation		Ruthee-Lu Bayer, MD	97	Phase II			Treatment		12-127A	Multiple Myeloma
295	NSLIJ	Ado-Trastuzumab Emtansine or Paclitaxel and Trastuzumab in Treating Patients with Stage I HER2-Positive Breast Cancer	Sara Michell Tolaney	Sara Michell Tolaney		Phase II	Dana-Farber Harvard Cancer Center; NCI	IIT; NCI	 Treatment	 18 and over	 13-048, NCI-2013-01818, ML28160, NCT01853748	Breast
296	LIJ; NSLIJ	Radiation Therapy with or without Cisplatin in Treating Patients with Recurrent Endometrial Cancer	Jonathan Michael Feddock	Veena Susan John, MD	95	Phase II	NRG Oncology; NCI	Coop Group; NCI	 Treatment	 Not specified	 GOG-0238, NCI-2009-00603, CDR0000550975, NCT00492778	Endometrius
297	NSHS-Children's	Radiation Therapy with or without Combination Chemotherapy or Pazopanib Hydrochloride before Surgery in Treating Patients with Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery	Aaron Robert Weiss	Carolyn Fein Levy, MD	91	Phase II/III	NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 2 and over	 ARST1321, NCI-2014-01340, NCT02180867	Sarcoma
298	Feinstein Institute	Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis		Jonathan Knisely, MD	175	Phase II/III			Treatment	18 years of age or older	13-465B	Mets; Spine
299	NSLIJ 	Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients with Localized Spine Metastasis	Samuel Ryu	Jonathan Knisely, MD	175	Phase II/III	NRG Oncology; NCI	Coop Group; NCI	 Treatment	 18 and over	 RTOG 0631, NCI-2009-01687, CDR0000646803, NCT00922974	Spine; Mets
300	NSLIJ; NSHS-SS; NSHS-Huntington	Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery	Deborah Schrag	Tony Philip, MD	101	Phase II/III	Alliance for Clinical Trials in Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 N1048, NCI-2012-00234, CDR0000715321, NCCTG-N1048, PN1048_A11PAMDREVW01, NCT01515787	Colorectal
301	NSLIJ 	Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients with Previously Untreated Chronic Lymphocytic Leukemia	Jennifer Ann Woyach	Amy Sharma, MD	144	Phase III	NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 65 and over	 A041202, NCI-2013-01220, ALLIANCE A041202, NCT01886872	Leukemia
302	Feinstein Institute	A Randomized Phase III Study of Bendamustine Plus Rituximab vs. Ibrutinib Plus Rituximab vs. Ibrutinib Alone in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL)		Amy Sharma, MD	144	Phase III			Treatment	65 years of age or older	E14-191	Leukemia
303	NSHS-Children's	Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma	Sharon M. Castellino	Arlene Sara Redner, MD	119	Phase III	NCI	NCI	 Biomarker/Laboratory analysis, Health services research, Supportive care, Treatment	 18 and younger	 AHOD1331, NCI-2014-01223, NCT02166463	Lymphoma
304	NSHS-Children's	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia	Michael J. Burke	Arlene Sara Redner, MD	119	Phase III	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 1 to 30	 AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, U10CA098543, NCT01406756	Leukemia
305	NSHS-Children's	Combination Chemotherapy with or without Bortezomib in Treating Younger Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma	David Trent Teachey	Arlene Sara Redner, MD	119	Phase III	NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 2 to 30	 AALL1231, NCI-2014-00712, NCT02112916	Leukemia; Lymphoma
306	NSHS-Children's	Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia	Richard Aplenc	Arlene Sara Redner, MD	119	Phase III	NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 Under 30	 AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981	Leukemia
307	NSHS-Children's	Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients with Cancer or Undergoing Donor Stem Cell Transplant	Danielle M. Zerr	Arlene Sara Redner, MD	119	Phase III	Children's Oncology Group; NCI	Coop Group; NCI	 Supportive care	 2 months to 21 years	 ACCL1034, NCI-2013-00595, COG-ACCL1034, NCT01817075	Peds
308	NSHS-Children's	Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma	Anne Lisette Angiolillo	Arlene Sara Redner, MD	119	Phase III	Children's Oncology Group; NCI	Coop Group; NCI	 Supportive care, Treatment	 1 to < 10	 AALL0932, NCI-2011-02599, CDR0000683227, COG-AALL0932, NCT01190930	Leukemia; Lymhoma
309	Feinstein Institute	A Randomized Phase III Study of Standard vs IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)		Beatrice Bloom, MD		Phase III			Treatment	18 years of age or older	13-176A	Endometrius; Cervix
310	LIJ; NSLIJ; NSHS-SS	Standard Radiation Therapy or Intensity-Modulated Pelvic Radiation Therapy in Treating Patients with Endometrial or Cervical Cancer	Ann H. Klopp	Beatrice Bloom, MD		Phase III	NRG Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Supportive care, Treatment	 18 and over	 RTOG 1203, NCI-2012-02001, CDR0000738944, NCT01672892	Endometrius; Cervix
311	NSHS-Children's	Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma	Patrick J. Leavey	Carolyn Fein Levy, MD	91	Phase III	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 50 and under	 AEWS1031, NCI-2011-02611, CDR0000687639, COG-AEWS1031, NCT01231906	Sarcoma
312	NSHS-Children's	Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer	Howard Mark Katzenstein	Carolyn Fein Levy, MD	91	Phase III	NCI	NCI	 Tissue collection/Repository, Treatment	 21 and under	 AHEP0731, NCI-2011-01975, CDR0000654889, COG-AHEP0731, NCT02265692, PAHEP0731_A08PAMDREVW01, NCT00980460	Liver
313	Feinstein Institute	A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less		Iuliana Shapira, MD		Phase III			Treatment	18 or older	C12-152	Breast
314	Feinstein Institute	A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS-1101 (CAL-101) as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia		Jacqueline Barrientos, MD	139	Phase III			Treatment	18 or older	12-06-85-03	Leukemia
315	LIJ; NSLIJ	Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Tait D. Shanafelt	Jacqueline Barrientos, MD	139	Phase III	NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 18 to 70	 E1912, NCI-2014-00118, ECOG-E1912, NCT02048813	Leukemia; Lymphoma
316	NSLIJ 	Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer	Kevin Michael Kalinsky	Jane E. Carleton, MD	94	Phase III	NCI	NCI	 Health services research, Treatment	 18 and over	 S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037	Breast
317	LIJ	Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer	Julie R. Gralow	Jane E. Carleton, MD	94	Phase III	NCI	NCI	 Health services research, Treatment	 18 and over	 S1007, NCI-2011-02623, CDR0000692475, SWOG-S1007, NCT01272037	Breast
318	NSHS-Children's	Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma	Holly J. Meany	Jonathan Fish, MD	116	Phase III	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 17 months and under	 ANBL1232, NCI-2014-00677, NCT02176967	CNS
319	NSHS-Children's	Isotretinoin with or without Dinutuximab, Aldesleukin, and Sargramostim following Stem Cell Transplant in Treating Patients with Neuroblastoma	Alice Lin-Tsing Yu	Jonathan Fish, MD	116	Phase III	NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 30 and under at diagnosis	 ANBL0032, NCI-2009-01064, CDR0000069018, COG-ANBL0032, COG-P9842, NCT00026312	CNS
320	NSLIJ 	Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine with or without Vorinostat in Treating Younger Patients with Previously Untreated Acute Myeloid Leukemia	Guillermo Garcia-Manero	Jonathan Kolitz, MD	67	Phase III	NCI	NCI	 Biomarker/Laboratory analysis, Treatment	 15 to 60	 S1203, NCI-2013-00490, PS1203_A06PAMDREVW01, SWOG-S1203, NCT01802333	Leukemia
321	Feinstein Institute	A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) vs IA with Vorinostat (NSC 701852) (IA+V) in Younger Patients with Untreated AML		Jonathan Kolitz, MD	67	Phase III			Treatment	between the ages of 18 and 60 years old	C13-179	Leukemia
322	LIJ; NSLIJ	Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer	Mariana Chavez-MacGregor	Lora Weiselberg, MD	104	Phase III	SWOG; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 S1207, NCI-2012-01995, CDR0000738280, SWOG-S1207, NCT01674140	Breast
323	NSLIJ 	Olaparib in Treating Patients with Triple-Negative Non-metastatic Breast Cancer Who Have Completed Definitive Local Treatment and Chemotherapy	Charles Edward Geyer	Lora Weiselberg, MD	104	Phase III	NRG Oncology; NCI	Coop Group; NCI	 Natural history/Epidemiology, Treatment	 18 and over	 NSABP-B-55, NCI-2014-00644, BIG 6-13, D081CC00006, NCT02032823	Breast
324	Feinstein Institute	Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating Adjuvant Endocrine Therapy +/- 1 Year of Everolimus in High-Risk, Hormone Receptor Positive and HER2/Neu Negative Breast Cancer		Lora Weiselberg, MD	104	Phase III			Treatment	18 years of age or older	E13-515	Breast
325	LIJ; NSHS-SS; NSLIJ	Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer	Alvaro Martinez	Louis Potters, MD	75	Phase III	NRG Oncology; NCI	Coop Group; NCI	 Treatment	 18 and over	 RTOG 0815, NCI-2011-01948, CDR0000648194, NCT00936390	Prostate
326	NSLIJ; NSHS-SS	Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer	Mack Roach	Louis Potters, MD	75	Phase III	NRG Oncology; NCI	Coop Group; NCI	 Treatment	 18 and over	 RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588	Prostate
327	Feinstein Institute	A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer		Louis Potters, MD	75	Phase III			Treatment	18 or older	09-293A	Prostate
328	Feinstein Institute	Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial		Louis Potters, MD	75	Phase III			Treatment	18 or older	11-372B	Prostate
329	LIJ; NSLIJ; NSHS-SS	Diet in Altering Disease Progression in Patients with Prostate Cancer on Active Surveillance	J. Kellogg Parsons	Manish Vira, MD	184	Phase III	Alliance for Clinical Trials in Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 50 to 80	 CALGB 70807, NCI-2011-02613, CDR0000687958, NCT01238172	Prostate
330	NSHS-Children's	Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Who Are Undergoing Chemotherapy	Theoklis E. Zaoutis	Mark P. Atlas, MD	129	Phase III	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Supportive care	 3 months to 30 years	 ACCL0933, NCI-2011-02640, CDR0000695748, COG-ACCL0933, NCT01307579	Leukemia
331	NSHS-Children's	Chemotherapy and Radiation Therapy in Treating Young Patients with Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma	James Michael Olson	Mark P. Atlas, MD	129	Phase III	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 3 to 21	 ACNS0332, NCI-2009-00336, CDR0000511991, COG-ACNS0332, NCT00392327	Brain
332	NSHS-Children's	Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma	Amy Amundson Smith	Mark P. Atlas, MD	129	Phase III	Children's Oncology Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 1 to 21	 ACNS0831, NCI-2011-02029, CDR0000668560, COG-ACNS0831, NCT01096368	Brain
333	NSHS-SI	Duloxetine Hydrochloride in Treating Muscle, Bone, and Joint Pain in Patients With Early-Stage Breast Cancer Receiving Hormone Therapy	Norah Lynn Henry	Meekoo Dhar, MD	149	Phase III	SWOG; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Supportive care	 Not specified	 S1202, NCI-2012-01960, CDR0000730691, SWOG-S1202, NCT01598298	Breast
334	NSHS-SI	Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery	Jeffrey A. Meyerhardt	Meekoo Dhar, MD	149	Phase III	Alliance for Clinical Trials in Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 CALGB 80702, NCI-2011-02050, CALGB/SWOG 80702, CALGB-SWOG C80702, CDR0000675693, NCT01150045	Colorectal
335	NSHS-SI	Early Surgery or Standard Palliative Therapy in Treating Patients with Stage IV Breast Cancer	Seema Ahsan Khan	Meekoo Dhar, MD	149	Phase III	ECOG-ACRIN Cancer Research Group; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 E2108, NCI-2011-02645, CDR0000688097, ECOG-E2108, NCT01242800	Breast
336	Feinstein Institute	A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer		Meekoo Dhar, MD	149	Phase III			Treatment		14-080	Breast
337	Feinstein Institute	Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV) (Protocol CDX110-04)		Michael Schulder, MD	77	Phase III			Treatment	18 years of age	11-06-282-03	Brain
338	NSHS-SI	Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer	Kevin Michael Kalinsky	Qun Dai, MD	141	Phase III	NCI	NCI	 Health services research, Treatment	 18 and over	 S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037	Breast
339	NSLIJ 	Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma	Paul Gerard Guy Richardson	Ruthee-Lu Bayer, MD	97	Phase III	Dana-Farber Harvard Cancer Center; NCI	IIT; NCI	 Treatment	 18 to 65	 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662	Multiple Myeloma
340	NSLIJ 	Doxepin Hydrochloride or DLA Rinse in Reducing Oral Mucositis Pain in Patients with Head and Neck Cancer undergoing Radiation Therapy	Robert C. Miller	Sewit Teckie, MD	182	Phase III	Alliance for Clinical Trials in Oncology; NCI	Coop Group; NCI	 Supportive care	 18 and over	 A221304, NCI-2014-01877, NCT02229539	Head & Neck
341	Feinstein Institute	A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial		Veena Susan John, MD	95	Phase III			Treatment	female 18 years of age or older	C13-137	Cervix
342	LIJ; NSLIJ	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients with Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	David S. Alberts	Veena Susan John, MD	95	Phase III	NRG Oncology; NCI	Coop Group; NCI	 Behavioral study, Biomarker/Laboratory analysis	 Not specified	 GOG-0225, NCI-2009-00595, CDR0000594600, NCT00719303	Ovary; Fallopian; Primary Peritoneal
343	LIJ; NSLIJ	Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer	Kathleen N. Moore	Veena Susan John, MD	95	Phase III	Gynecologic Oncology Group; NCI	Coop Group; NCI	 Supportive care, Treatment	 18 and over	 ANZGOG-0902/GOG-0274/RTOG-1174, NCI-2011-02978, ANZGOG-0902, CDR0000706698, GOG-0274, RTOG-1174, ANZGOG-0902-GOG-0274, NCT01414608	Cervix
344	LIJ; NSLIJ	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride with or without Bevacizumab after Surgery in Treating Patients with Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer	Robert L. Coleman	Veena Susan John, MD	95	Phase III	NCI	NCI	 Treatment	 18 and over	 GOG-0213, NCI-2009-00587, CDR0000546714, NCT00565851	Ovary; Fallopian; Primary Peritoneal
345	LIJ; NSLIJ;	Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery	Jeffrey A. Meyerhardt	Vincent Vinciguerra, MD	85	Phase III	Alliance for Clinical Trials in Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 CALGB 80702, NCI-2011-02050, CALGB/SWOG 80702, CALGB-SWOG C80702, CDR0000675693, NCT01150045	Colorectal
346	Feinstein Institute	Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)		Vincent Vinciguerra, MD	85	Phase III			Treatment	18 or older	10-157B	Liver
347	Feinstein Institute	A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer		Vincent Vinciguerra, MD	85	Phase III			Treatment	18 or older	10-295A	Colorectal
348	NSLIJ 	Enzalutamide with or without Abiraterone Acetate and Prednisone in Treating Patients with Castration-Resistant Metastatic Prostate Cancer	Michael J. Morris	Xinhua Zhu, MD, PhD	145	Phase III	Alliance for Clinical Trials in Oncology; NCI	Coop Group; NCI	 Biomarker/Laboratory analysis, Treatment	 18 and over	 A031201, NCI-2013-01737, CALGB-A031201, NCT01949337	Prostate; Mets
349	Feinstein Institute	Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer		Xinhua Zhu, MD, PhD	145	Phase III			Treatment	18 Years and older	E14-266	Prostate